Enimmune Corporation (TPEX:6564)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
19.95
+0.15 (0.76%)
At close: Feb 11, 2026
Market Cap1.44B -26.0%
Revenue (ttm)42.23M -16.9%
Net Income-164.74M
EPS-2.22
Shares Out72.13M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume38,960
Average Volume86,894
Open19.90
Previous Close19.80
Day's Range19.35 - 20.00
52-Week Range14.65 - 27.10
Beta0.39
RSI44.53
Earnings DateApr 17, 2026

About Enimmune

Enimmune Corporation engages in the research, development, and sale of drugs in Taiwan. The company offers EnVAX-A71, AimFlu-S(QIS), tetanus vaccine adsorbed suspension for injection, COVID-19 Ag rapid test, vaccines, test reagents, and related western medicines, as well as biotechnology services. It is also involved in the development of vaccines for the prevention of infectious diseases, including pneumococcus, norovirus, dengue fever virus, and Middle East respiratory syndrome, such as cell culture-derived Japanese encephalitis vaccine, whic... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6564
Full Company Profile

Financial Performance

In 2024, Enimmune's revenue was 39.92 million, a decrease of -8.23% compared to the previous year's 43.49 million. Losses were -157.55 million, -29.59% less than in 2023.

Financial Statements